BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jabbari P, Hanaei S, Rezaei N. State of the art in immunotherapy of neuroblastoma. Immunotherapy 2019;11:831-50. [PMID: 31094257 DOI: 10.2217/imt-2019-0018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Yan P, Qi F, Bian L, Xu Y, Zhou J, Hu J, Ren L, Li M, Tang W. Comparison of Incidence and Outcomes of Neuroblastoma in Children, Adolescents, and Adults in the United States: A Surveillance, Epidemiology, and End Results (SEER) Program Population Study. Med Sci Monit 2020;26:e927218. [PMID: 33249420 DOI: 10.12659/MSM.927218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Seier JA, Reinhardt J, Saraf K, Ng SS, Layer JP, Corvino D, Althoff K, Giordano FA, Schramm A, Fischer M, Hölzel M. Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma. J Immunother Cancer 2021;9:e001335. [PMID: 34016720 DOI: 10.1136/jitc-2020-001335] [Reference Citation Analysis]
3 Mokhtari RB, Sambi M, Qorri B, Baluch N, Ashayeri N, Kumar S, Cheng HM, Yeger H, Das B, Szewczuk MR. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers (Basel) 2021;13:3596. [PMID: 34298809 DOI: 10.3390/cancers13143596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Raieli S, Di Renzo D, Lampis S, Amadesi C, Montemurro L, Pession A, Hrelia P, Fischer M, Tonelli R. MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma. Front Oncol 2021;11:625207. [PMID: 33718189 DOI: 10.3389/fonc.2021.625207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wang Y, Luo H, Cao J, Ma C. Bioinformatic Identification of Neuroblastoma Microenvironment-Associated Biomarkers with Prognostic Value. J Oncol 2020;2020:5943014. [PMID: 32963529 DOI: 10.1155/2020/5943014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Walker SM. Neuropathic pain in children: Steps towards improved recognition and management. EBioMedicine 2020;62:103124. [PMID: 33248373 DOI: 10.1016/j.ebiom.2020.103124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Xu WL, Shi BJ, Li SL, Yu FX, Guo LN, Li M, Hu ZG, Li GX, Zhou H. Targeted inhibition of myeloid-derived suppressor cells in the tumor microenvironment by low-dose doxorubicin to improve immune efficacy in murine neuroblastoma. Chin Med J (Engl) 2020;134:334-43. [PMID: 33278092 DOI: 10.1097/CM9.0000000000001234] [Reference Citation Analysis]
8 Huang C, Jiang S, Yang J, Liao X, Li Y, Li S. Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification. Medicine (Baltimore) 2020;99:e20853. [PMID: 32569234 DOI: 10.1097/MD.0000000000020853] [Reference Citation Analysis]
9 Sawaisorn P, Atjanasuppat K, Anurathapan U, Chutipongtanate S, Hongeng S. Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. Vaccines (Basel) 2020;8:E753. [PMID: 33322408 DOI: 10.3390/vaccines8040753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]